Patents by Inventor Lijuan HAO

Lijuan HAO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11136387
    Abstract: The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: October 5, 2021
    Assignee: SHANGHAI PHARMAEXPLORER CO., LTD.
    Inventors: Yizhen Yang, Shiyong Gong, Lijuan Hao, Jian Wu, Xinxiu Yang, Qin Zhong, Shaoping Hu, Stewart Leung, Qing Duan, Lile Liu
  • Publication number: 20190309059
    Abstract: The present invention discloses IL-13 antibody, method of its preparation and use thereof. The IL-13 antibody comprises one or more of heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 of heavy chain variable region of the IL-13 antibody, and/or one or more of light chain CDR1, light chain CDR2, and light chain CDR3 of light chain variable region of the IL-13 antibody. The IL-13 antibody has a high affinity and can significantly inhibit the secretion of thymus activation-regulated chemokine and periostin as well as the expression of vascular cell adhesion molecule-1 induced by IL-13, it can significantly inhibit airway hyperresponsiveness in mice induced by IL-13, and therefore can be used in the preparation of drugs for preventing or treating IL-13 expression or dysfunction related diseases.
    Type: Application
    Filed: May 16, 2017
    Publication date: October 10, 2019
    Applicant: SHANGHAI PHARMAEXPLORER CO., LTD.
    Inventors: Yizhen YANG, Shiyong GONG, Lijuan HAO, Jian WU, Xinxiu YANG, Qin ZHONG, Shaoping HU, Stewart LEUNG, Qing DUAN, Lile LIU
  • Publication number: 20180060463
    Abstract: A hybrid Mote Carlo and deterministic particle transport method based on the transition area is provided. Firstly, the geometric complexity is analyzed based on the CAD model. Based on the geometric complexity and the physical characteristics, an area having complex geometry is divided as a Monte Carlo particle transport calculation area, an area having simple geometry is divided as a deterministic particle transport calculation area, and a transition area with a determined thickness is created between the two areas. In the particle transport calculation, the Monte Carlo particle transport calculation is performed in the Monte Carlo particle transport area and the transition area, and the deterministic calculation is performed in the deterministic area and the transition area. Basically consistent results of the transition area under the two calculations can be achieved through multiple iterations, thereby realizing seamless coupling of the two calculations.
    Type: Application
    Filed: July 28, 2017
    Publication date: March 1, 2018
    Applicant: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CAS
    Inventors: Yican WU, Liqin HU, Pengcheng LONG, Lijuan HAO, Jing SONG